Headquartered at the International Innovation Center in Beijing Daxing Lingang Economic Zone, the company operates state-of-the-art independent R&D facilities. Its pipeline has achieved significant milestones:
Pipeline
- Systemic Sclerosis: completed Phase I clinical trials and poised to advance to Phase II.
-Localized Sclerosis: received approval for Investigational New Drug (IND) applications in 2023, with Phase II trials imminent.
- Diabetic Foot Ulcer: secured approval for Investigational New Drug (IND) applications in 2024, marking rapid progress in addressing critical unmet medical needs.
The company has established proprietary platforms for pharmaceutical research and efficacy evaluation, underpinned by independent intellectual property. These platforms enable the development of diverse cell-based therapies, positioning Aegle Stem as a pioneer in innovative regenerative medicine solutions.
By integrating academic excellence with industrial innovation, Aegle Stem aims to deliver transformative treatments for complex diseases globally.
